ARMP (Armata Pharmaceuticals) חוב לטווח קצר להון

Armata Pharmaceuticals develops treatments against antibiotic-resistant pathogens, collaborating with scientific centers on respiratory drug trials. This chart of the current share price on the GURU.Markets platform, where the indicator equals 0.00, demonstrates high resilience to economic cycles and an absence of seasonality. However, a narrow specialization in phages creates significant risks that require constant capital injections from major investors.

This ratio reflects the proportion of short-term liabilities relative to the company's equity. The metric assesses the business's dependence on rapid debt financing and the risk level of losing solvency. By analyzing the short-term debt-to-equity chart, an investor determines the stability of the liability structure. For Armata Pharmaceuticals (ARMP), this balance is critical when implementing costly alliances for bacteriophage development.